stockrowTherapeuticsMD, Inc.
TXMDHealthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024.
- Revenue
- −8.72%
- EPS
- −80.0%
- Free cash flow
- +104.5%
Quarter to June 2026, against a year earlier
Follow TXMD
Alert me
TherapeuticsMD, Inc. (TXMD) Return on invested capital
TherapeuticsMD, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −13.8%, up 0.4 percentage points from fiscal 2025 (−14.2%). Over the past ten years it has ranged from −1,749.6% (fiscal 2017) to 0.00% (fiscal 2022); the current reading is higher than 73% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −14.2% | 2.97 |
| FY2024 | −17.1% | 4.22 |
| FY2023 | −21.3% | (21.34) |
| FY2022 | 0.00% | 167.23 |
| FY2021 | −167.2% | 106.88 |
| FY2020 | −274.1% | (61.78) |
| FY2019 | −212.3% | 663.56 |
| FY2018 | −875.9% | 873.70 |
| FY2017 | −1,749.6% | (1,749.59) |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IXHL Incannex Healthcare Inc. compare | 0.00% |
| OPTH Optimi Health Corp. compare | 0.00% |
| CPHI China Pharma Holdings, Inc. compare | −7.23% |
| TXMD TherapeuticsMD, Inc. | −13.8% |
| RMTI Rockwell Medical, Inc. compare | −14.6% |
| AYTU Aytu BioPharma, Inc. compare | −20.0% |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | −36.7% |
| BFRI Biofrontera Inc. compare | −69.5% |
| SCYX SCYNEXIS, Inc. compare | −110.7% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)